HOME > TOP STORIES

TOP STORIES

ORGANIZATION NPhA Compiles Draft Proposal for Mutual Understanding to Improve Distribution

February 10, 2012
BUSINESS Teijin Aims for ¥400 Billion in Sales in Healthcare by FY2020

February 9, 2012
BUSINESS Novartis President Mitani Says Diovan Patent Expiry an “Urgent Issue”

February 8, 2012
BUSINESS JCR to Push Joint Development with GSK, Including New Biopharmaceuticals

February 7, 2012
BUSINESS US, European Pharmaceutical Companies Supported by Steady Japan Business Growth

February 6, 2012
BUSINESS Number of MRs Breaks 60,000; Could Become Major Topic in Light of Strained Healthcare Finances

February 6, 2012
BUSINESS Eisai Says Impact from Generic Versions of Aricept Insignificant

February 3, 2012
BUSINESS Chugai Pharmaceutical to Promote Executive VP Kosaka as President and COO

February 2, 2012
BUSINESS Kyowa Kirin Development Chief Hanai Set to Become Company President

February 1, 2012
REGULATORY CSIMC General Assembly Establishes Premium for Prescriptions by Generic Name

January 31, 2012
REGULATORY JPO Decides Lipitor Crystal Form “Valid”, Sandoz Calls for Appeal

January 30, 2012
ORGANIZATION JPWA Board of Directors Approve By-Category Talks to Be Common Understanding

January 27, 2012
REGULATORY Rule Review in Similar Drug Re-Pricing Yields 50 Exemptions Based on Competitiveness

January 26, 2012
REGULATORY 16 APIs Including Aricept, Lyrica to Be Re-Priced for Market Expansion

January 25, 2012
BUSINESS Mochida President Hopes to Ease Impact of Next NHI Price Revision with New Drugs

January 24, 2012
BUSINESS Growell President Takada Says Ready for Legal Action on Stoppage of “Dispensing Point” System

January 23, 2012
REGULATORY PMDA to Introduce Direct ADR Reporting System for Patients on Trial Basis

January 20, 2012
BUSINESS Takeda President Hasegawa Envisions Japanese National as Successor

January 19, 2012
BUSINESS Nexium Dominates Top 2 Rankings in HP Market 2 Months in a Row: RepTrack Dec. Survey

January 18, 2012
ORGANIZATION JPWA, NPhA Hold Talks for Distribution Improvement

January 18, 2012

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…